ACC 2019 Program/Itinerary Planner is live. Resverlogix in da house! Although it seems far-fetched due to BETonMACE not yet hitting 250 events and needing time for adjudication/patient follow ups, stay tuned for end of January announcement of Late Breaking Clinical Trial Sessions to find out if BETonMACE gets a slot. Regardless, a couple of poster presentations on tap.

March 16 Poster: Session 1135 - Vascular Medicine: Basic 1

1135-454 / 454 - Apabetalone, an Epigenetic BET Inhibitor in a Phase 3 Trial, Inhibits Vascular Inflammation and Cellular Adhesion Leading to Beneficial Outcomes in CVD Patients

March 18 Poster: Session 1331 - Prevention: Clinical 5

1331-413 / 413 - BET Protein Inhibition and Cognition: A Pre-Specified Substudy of the BETonMACE Phase 3 Trial Evaluating Apabetalone in Patients With Diabetes and Acute Coronary Syndrome